Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) SVP Andrew Davis sold 5,360 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $21,868.80. Following the completion of the transaction, the senior vice president now owns 284,685 shares of the company’s stock, valued at approximately $1,161,514.80. This trade represents a 1.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ironwood Pharmaceuticals Stock Performance
NASDAQ IRWD traded down $0.29 on Wednesday, reaching $3.52. 1,613,600 shares of the company’s stock traded hands, compared to its average volume of 2,895,659. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $15.70. The stock has a 50 day moving average price of $4.27 and a 200-day moving average price of $5.39. The firm has a market cap of $563.31 million, a price-to-earnings ratio of -127.00 and a beta of 0.47.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 EPS. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Ironwood Pharmaceuticals
Hedge Funds Weigh In On Ironwood Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Ironwood Pharmaceuticals by 21.8% in the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after buying an additional 3,487,821 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after buying an additional 2,400,000 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 26.6% during the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock valued at $46,473,000 after acquiring an additional 2,372,183 shares in the last quarter. Kynam Capital Management LP acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $14,154,000. Finally, Renaissance Technologies LLC grew its position in shares of Ironwood Pharmaceuticals by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after buying an additional 1,472,097 shares during the last quarter.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
Read More
- Five stocks we like better than Ironwood Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Best Stocks Under $10.00
- Williams-Sonoma Stock: Buy It and Never Let It Go
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.